Despite the relative scarcity of research on the correlation between NLRC3 and SLE, this study discovered that triptoquinone A and triptoquinone B, the active ingredients of TGTs, can identify potential genetic genes and drugs for SLE-related arthritis prevention by binding to the target molecule NLRC3. The gene discussed is NLRC3; the disease is systemic lupus erythematosus.